Organization | Agilent Technologies, Inc.

Agilent Technologies, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Santa Clara CA United States (1999)

Status: No NME R&D (1999)

Organization Overview

First Clinical Trial

2016

NCT02452697

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (5)

Key: Agilent Technologies, Inc. (0) Acquired (5)

cyclophosphamide (cytoxan) (1 trial)

docetaxel (taxotere) (1 trial)

doxorubicin (Doxil) (2 trials)

epirubicin (ellence) (1 trial)

memantine (namenda) (1 trial)

Drugs in Phase 2 Trials (14)

Key: Agilent Technologies, Inc. (2) Acquired (12)

allogeneic natural killer cells (1 trial)

carboplatin (paraplatin) (1 trial)

cisplatin (platinol) (1 trial)

duk-cpg-001 (1 trial)

fludeoxyglucose f-18 (1 trial)

gemcitabine (gemzar) (1 trial)

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) (1 trial)

niraparib (zejula) (1 trial)

nivolumab (opdivo) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

pemetrexed (alimta) (1 trial)

relugolix (ORGOVYX) (1 trial)

(s)-4-(3-fluoropropyl)-l-glutamic acid (1 trial)

Drugs in Phase 1 Trials (3)

Key: Agilent Technologies, Inc. (0) Acquired (3)

ef5 (1 trial)

pimonidazole (1 trial)

sodium alginate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Neoplasms (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial APIs: 22